The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1317
ISSUE1317
July 27, 2009
Corrections: Biannual IV Zoledronic Acid (Reclast) for Prevention of Osteoporosis and Golimumab (Simponi) for Inflammatory Arthritis
Download PDF: US English
Med Lett Drugs Ther. 2009 Jul 27;51(1317):60
Disclosures
Objective(s)
Corrections:
Biannual IV Zoledronic Acid (Reclast) for Prevention of Osteoporosis (Med Lett Drugs Ther 2009; 51:49)
The first word of the title should have been Biennial, not Biannual.
Golimumab (Simponi) for Inflammatory Arthritis (Med Lett Drugs Ther 2009; 51:55)
In Table 1 on page 55, the price for certolizumab (Cimzia) should have been $1,341.68 (not $3,136.40).
© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and
complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any
damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
Previous article